Astria Therapeutics
We have no price for Astria Therapeutics since 23 January 2026. It may have been taken over, merged or renamed, so the figures below are from then.
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
Astria Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Astria Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Astria Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
What analysts expect
- Average price target
- $19.40
- Range
- $13.00 – $26.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Nov 12, 2025 | -0.55 | -0.41 | −34.1% |
| Aug 12, 2025 | -0.57 | -0.61 | +6.6% |
| May 13, 2025 | -0.58 | -0.48 | −20.8% |
| Mar 11, 2025 | -0.44 | -0.45 | +2.2% |
| Nov 13, 2024 | -0.42 | -0.42 | +0.0% |
| Aug 12, 2024 | -0.43 | -0.37 | −16.2% |
| May 9, 2024 | -0.38 | -0.35 | −8.6% |
| Mar 4, 2024 | -0.86 | -0.69 | −24.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about Astria Therapeutics
Is Astria Therapeutics a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Astria Therapeutics AI analysis
What does Astria Therapeutics do?
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. It is in Biotechnology.
Who are Astria Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Astria Therapeutics's.
Prices: daily closes to Jan 23, 2026. Fundamentals: company reports via invest-like data.